A recent study has sparked an intriguing debate in the medical community, challenging our understanding of diabetic ketoacidosis (DKA) risk in type 1 diabetes (T1D). The study, published in Diabetes Care, reveals a surprising finding: low levels of kidney function, measured by eGFR rates, do not seem to increase the risk of DKA in adults with T1D. This is a controversial claim, as it contradicts previous research and raises questions about our current treatment approaches.
Unraveling the DKA Mystery: A New Perspective
In people with type 2 diabetes, SGLT inhibitors have been a game-changer, reducing late-stage kidney complications. However, these medications also come with an increased DKA risk. But here's where it gets controversial: when it comes to T1D, these inhibitors are not routinely approved, despite the fact that about 30% of individuals with T1D develop chronic kidney disease. This gap in treatment options led researchers to investigate the impact of reduced kidney function on DKA risk.
The DCCT/EDIC Study: Uncovering Trends
Researchers analyzed an extensive dataset from the DCCT/EDIC study, spanning an impressive 35 years. The study population consisted of 1441 adults with T1D, with an average diabetes duration of approximately 6 years. During the 34-year follow-up period, an interesting trend emerged: 297 participants experienced at least one DKA event, totaling 488 events. The key finding? There was no significant difference in DKA rates between individuals with an eGFR between 30 and 90 mL/min/1.73 m2 compared to those with an eGFR between 90 and 120 mL/min/1.73 m2, which served as the reference range.
Adjusted Analysis: A Closer Look
When the researchers adjusted their analysis, they found that the hazard ratio (HR) for the first DKA among those with an eGFR above 120 mL/min/1.73 m2 was not significantly higher than the reference group (HR, 1.33). This suggests that even with higher eGFR rates, the risk of DKA remains relatively stable.
Limitations and Strengths: A Balanced Perspective
The study had its limitations, including the relatively young and healthy volunteer participants, the lack of central adjudication to confirm DKA, and missing data on potentially confounding variables. However, the study's strengths lie in its large size and long time frame, providing a robust dataset to work with.
Contrasting Findings: A Different Perspective
Interestingly, the study's findings contrast with those of the FinnDiane study, which reported a higher DKA risk among individuals with baseline end-stage kidney disease and those with an eGFR of 60 mL/min/1.73 m2 or lower. The researchers suggest that their time-updated analysis, which classified eGFR levels immediately preceding each DKA event, may provide a more accurate risk assessment compared to the FinnDiane study.
Looking Ahead: Safer Treatment Options
The study's lead researcher, Abdulmohsen Bakhsh, MD, believes that ongoing SGLT inhibitor trials in T1D, along with emerging tools like continuous ketone monitors, could lead to safer and more targeted use in selected patients. He emphasizes the need for future studies to assess DKA risk in patients with established CKD, including those with eGFR below 30 mL/min/1.73 m2, and to explore implementation strategies like education and ketone monitoring to mitigate DKA risks.
A Call for Further Research: Clarifying the DKA-Kidney Function Link
Charles Leonard, PharmD, MSCE, MPH, an associate professor at the Perelman School of Medicine, University of Pennsylvania, highlights the importance of distinguishing causation from correlation. He believes that while the new data is noteworthy, the wide confidence intervals at the lowest eGFR levels and the study's focus on statistical significance make the evidence less convincing. Leonard calls for further research, such as a rigorously designed prospective study, to better define the kidney-benefit versus DKA-risk balance in T1D, especially in advanced kidney disease where uncertainty remains high.
This study challenges our understanding of DKA risk in T1D and highlights the need for further research to clarify the link between kidney function and DKA. As we navigate this complex landscape, the medical community must continue to explore and discuss these findings, ensuring the best possible care for individuals with T1D. What are your thoughts on this study's findings? Do you think it opens up new avenues for treatment and research? Share your insights in the comments below!
